LivaNova PLC
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vladimir A. Makatsaria
- Full Time Employees
- 2,900
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 20 Eastbourne Terrace London United Kingdom W2 6LG
- IPO Date
- Oct 19, 2015
- CIK
- 0001639691
- Website
- livanova.com
- Similar Companies
- Business
- LivaNova PLC (Nasdaq: LIVN) develops and markets medical devices focused on cardiopulmonary surgery and neuromodulation therapies for neurological and psychiatric disorders. The company offers a comprehensive portfolio including the Essenz heart-lung machine platform and related perfusion systems, high-performance oxygenators for adult and pediatric patients, autotransfusion systems, cannulae, perfusion tubing disposables; and the VNS Therapy system providing vagus nerve stimulation for drug-resistant epilepsy, difficult-to-treat depression and obstructive sleep apnea, alongside the aura6000 system for proximal hypoglossal nerve stimulation. LivaNova operates globally in over 100 countries with manufacturing sites in Italy, the United States and Canada; it was formed in 2015 through the merger of Sorin SpA and Cyberonics Inc. and maintains headquarters in London, UK. Recent developments include raising full-year 2025 revenue growth guidance to 8.5%-9.5% constant currency following Q3 2025 results that showed 12.5% organic revenue growth driven by Essenz sales and cardiopulmonary consumables; unveiling a 2030 strategic roadmap targeting high-single-digit-plus revenue CAGR, adjusted operating margins in the high-twenties and an independent US commercial launch for obstructive sleep apnea therapy in 2027; securing CMS reimbursement enhancements effective January 2026 that boost hospital payments for VNS Therapy implants by approximately 48%; initiating Essenz commercial launch in China; appointing Lucile Blaise as Global Head of Commercialization for Obstructive Sleep Apnea and Donald Zurbay to the Board of Directors in late 2025; and presenting long-term real-world data at medical conferences demonstrating up to 95% median seizure reductions with VNS Therapy at 36 months alongside health economics benefits including reduced hospitalizations.
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
Aberdeen Group plc Lowers Stock Holdings in LivaNova PLC $LIVN
SG Americas Securities LLC Buys 11,066 Shares of LivaNova PLC $LIVN
Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LivaNova to Announce First-Quarter 2026 Results
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Brokerages